Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G

Little is known about the anti‐tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD‐L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohisto...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Thorac Cancer
Main Authors: Suyama, Takayuki, Fukuda, Yuichi, Soda, Hiroshi, Ogawara, Daiki, Iwasaki, Keisuke, Hara, Takuya, Yoshida, Masataka, Harada, Tatsuhiko, Umemura, Asuka, Yamaguchi, Hiroyuki, Mukae, Hiroshi
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2018
Teme:
Case Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983224/
https://ncbi.nlm.nih.gov/pubmed/29667757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12644
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki